痛风患者如何选择饮食疗法？

字号 + –

12 10月 2019

1
2
3
4
5

Author : 伤口世界

原创：卢魁

痛风之痛:
尿酸盐在体内大量沉积形成结晶，体表、手脚关节部位会慢慢长出痛风石，时间长了会导致关节破坏、关节畸形，影响正常功能。尿酸盐长期沉积在肾脏，会引发痛风性肾病，严重的甚至导致尿毒症。

痛风患者还常伴发有高脂血血症、高血压、糖尿病及冠心病。痛风久治不愈、反复发作也会形成慢性伤口。一般人正常膳食每天摄人嘌呤600~1000毫克，痛风急性发作期摄人量应控制在150 毫克以内，缓解期也应遵循低嘌呤饮食。
食物嘌呤含量参考
嘌呤含量> 150 毫克/100克。动物内脏：肝、肾、脑、脾、肠；部分水产：带鱼、鲶鱼、鲢鱼、沙丁鱼、凤尾鱼、基围虾等。肉汤、鱼汤、海鲜火锅汤。
嘌呤含量在75-150毫克|100克。猪、牛、羊肉、鸡鸭等；鲈鱼、鲤鱼、鲫鱼、草鱼；螃蟹；黑豆、黄豆、绿豆等。
嘌呤含量在30-75毫克/100克。菠菜、芦笋、毛豆、豌豆、三文鱼、金枪鱼及豆浆、豆干、豆皮、腐竹、豆腐等。
嘌呤含量< 30毫克/100克。大白菜、土豆、芋头、白薯、木薯、番茄、茄子、冬瓜。部分杂粮：小米、荞麦、燕麦；葡萄、苹果、草莓；米饭、馒头等。

1715 Views

伤口世界

电子邮件地址该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

Latest from 伤口世界

K2 Content

保湿润肤类产品应用指导专家共识（2023版） 2026-05-19 00:00

中国医师协会皮肤科医师分会

通信作者：郝飞，Email：该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。；高兴华，Email：该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【摘要】应用保湿润肤类产品是保护或修护皮肤屏障、维护皮肤健康和防治皮肤病的重要手段。为规范及合理应用保湿润肤类产品，中国医师协会皮肤科医师分会组织国内有关专家，结合国内外研究现状，就保湿润肤类产品的功效、成分选择、应用指征、使用法、不良反应及注意事项等深入讨论并达成此共识。

【关键词】皮肤；保湿润肤类产品；合理应用；皮肤屏障；专家共识

DOI：10.35541/cjd.20230133

Guidance on application of moisturizers and emollients: an expert consensus（2023）

China Dermatologist Association

Corresponding authors: Hao Fei, Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。; Gao Xinghua, Email: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。

【Abstract】 The application of moisturizers and emollients is an important method for protecting or repairing skin barriers, maintaining skin health, and coping with skin diseases. In order to standardize and rationalize the application of moisturizers and emollients, the China Dermatologist Association convened Chinese experts in this field to conduct sessions of in⁃depth discussions based on up⁃to⁃date Chinese and international research outcomes, and reached a consensus on the efficacy, composition selection, application indications, application methods and adverse reactions of moisturizers and emollients, as well as considerations during their use.

【Key words】

Skin; Moisturizers and emollients; Rational application; Skin barriers; Expert consensus

DOI: 10.35541/cjd.20230133

皮肤屏障功能维持着机体内环境稳定［1］。遗传基因异常、生理性衰退及各种疾病等均可破坏皮肤完整性，导致屏障功能障碍，进一步影响皮肤健康乃至疾病的发生和发展［2］。因此，使用保湿润肤类产品成为保护和修复皮肤屏障的重要措施。为规范及合理应用保湿润肤类产品，中国医师协会皮肤科医师分会组织国内有关专家，结合国内外研究现状，就保湿润肤类产品的功效、成分选择、应用指征、使用方法、不良反应及注意事项等深入讨论并达成应用指导的专家共识。

本共识文献检索自Medline、PubMed、Cochrane协作网、中国知网、万方医学网等数据库，关键词包括但不限于：moisturizer、emollient、skincare、skinbarrier、保湿润肤类产品、保湿剂、润肤剂、护肤品、皮肤屏障、天然保湿因子、特应性皮炎（atopicdermatitis，AD）、玫瑰痤疮、敏感性皮肤、经表皮失水率等，检索起始时间不限，大部分参考文献为2010年后最新发表。文中近30条重要结论均经过专家组Delphi问询法论证。
The Skin Barrier and Moisturization: Function, Disruption, and Mechanisms of Repair 2026-05-18 00:00

Jeffrey Rajkumara Neha Chandana Peter Liob Vivian Shic

a Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA;

b Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;

c Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock, AK, USA

Keywords

Skin barrier · Barrier disruption · Moisturizers

Abstract

Background: The anatomic layers of the skin are well-defined, and a functional model of the skin barrier has recently been described. Barrier disruption plays a key role in several skin conditions, and moisturization is recommended as an initial treatment in conditions such as atopic dermatitis. This review aimed to analyze the skin barrier in the context of the function model, with a focus on the mechanisms by which moisturizers support each of the functional layers of the skin barrier to promote homeostasis and repair. Summary: The skin barrier is comprised of four interdependent layers – physical, chemical, microbiologic, and immunologic – which maintain barrier structure and function. Moisturizers target disruption affecting each of these four layers through several mechanisms and were shown to improve transepidermal water loss in several studies. Occlusives, humectants, and emollients occlude the surface of the stratum corneum (SC), draw water from the dermis into the epidermis, and assimilate into the SC, re- spectively, in order to strengthen the physical skin barrier. Acidic moisturizers bolster the chemical skin barrier by sup-porting optimal enzymatic function, increasing ceramide production, and facilitating ideal conditions for commensal microorganisms. Regular moisturization may strengthen the immunologic skin barrier by reducing permeability and subsequent allergen penetration and sensitization. Key Messages: The physical, chemical, microbiologic, and im-munologic layers of the skin barrier are each uniquely impacted in states of skin barrier disruption. Moisturizers target each of the layers of the skin barrier to maintain homeostasis and facilitate repair.
GLP-1 receptor agonists and coronary plaques regression in diabetic patients after acute coronary syndromes 2026-05-16 00:00

Mauro Gitto1,2 · Federica Catapano1,2 · Marco Francone1,2 · Gianluca Mincione1,2 · Vincenzo Scialò1,2 ·Carlo A. Pivato1,2 · Costanza Lisi1,2 · Damiano Regazzoli1,2 · Davide Cao1,2 · Roberta Maria Fiorina1 ·Alessandra Petrelli3,4 · Loredana Bucciarelli4 · Cristian Loretelli3,4 · Gianluigi Condorelli1,2 · Paolo Fiorina3,4,5 · Giulio Stefanini1,2

Received: 4 October 2025 / Accepted: 15 October 2025 / Published online: 4 November 2025 © The Author(s) 2025

Abstract

Background Despite advances in therapeutic strategies a significant proportion of acute coronary syndrome (ACS) patients experience early coronary artery disease (CAD) progression, particularly those with diabetes.

Aim To evaluate CAD progression in diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1Ra) over 1 year after an ACS.

Methods Patients presenting with non–ST-elevation ACS between 2019 and 2022 were enrolled in a prospective registry and underwent serial coronary computed tomography angiography (CCTA) at baseline (after revascularization, during the index hospitalization) and at 1-year follow-up. The primary endpoint was the absolute change (1 year – baseline) in non-culprit lesion plaque burden (ΔPB) on CCTA, with the absolute change in patient percent atheroma volume (ΔPAV) as a key secondary endpoint. A comprehensive lipidomic, metabolomic, and proteomic plasma assessment was also performed in all GLP-1Ra–treated patients and four randomly selected controls.

Results Of 28 diabetic patients, 7 (25%) with 22 coronary plaques were treated with GLP-1Ra, and 21 (75%) with 65 plaques received other antidiabetic agents. In the 1-year observation frame, both ΔPB (-5.8±12.8% vs. -1.1±13.6%, p=0.041) and ΔPAV (-6.1% [-7.3, -1.8] vs. -0.7% [-2.4, 9.8], p=0.039) were significantly lower in GLP-1Ra-treated patients. Total atheroma volume also showed a numerically greater reduction in the GLP-1Ra cohort (0.7 mm³ [-2.5-8.7] vs. 25.0 mm³ [4.8–39.7]), primarily due to a decrease in plaque fibrofatty volume percentage (-2.9±10.1% vs. 1.0±6.8%, p=0.042). Lipi-domic, metabolomic, and proteomic analyses identified reductions in monoacylglycerols and triacylglycerols, increases in diacylglycerols and phosphatidylethanolamine, a shift from carbohydrate metabolism toward lipid metabolism and hormone regulation, and differential expression of proteins involved in complement activation, endothelial function, and cytoskeletal organization in GLP-1Ra–treated patients compared with controls.

Conclusions In diabetic patients with ACS, GLP-1Ra therapy was associated with a significant regression in coronary plaque burden at 1 year, supported by favorable lipidomic, metabolomic, and proteomic changes. These findings suggest a potential role for GLP-1Ra in modifying atherosclerosis progression beyond glycemic control.

Keywords GLP-1 receptor agonists · Diabetes mellitus · Coronary artery disease · Acute coronary syndrome · Plaque regression

Custom Mod Mega1

主任医师、教授、博导，南方医科大学第三附属医院（广东省骨科医院）院长